Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. trimmed its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 2.1% in the third quarter, HoldingsChannel.com reports. The firm owned 46,556 shares of the medical research company’s stock after selling 989 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Charles River Laboratories International were worth $9,170,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Tortoise Investment Management LLC boosted its holdings in shares of Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after buying an additional 57 shares in the last quarter. Headlands Technologies LLC acquired a new position in Charles River Laboratories International in the first quarter valued at $41,000. Wolff Wiese Magana LLC purchased a new position in shares of Charles River Laboratories International during the third quarter worth about $32,000. Assetmark Inc. increased its position in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after purchasing an additional 173 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of Charles River Laboratories International by 219.3% in the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 193 shares during the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on CRL. TD Cowen lifted their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday. The Goldman Sachs Group cut their target price on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. UBS Group lifted their price objective on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, Robert W. Baird decreased their target price on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, September 20th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Hold” and a consensus target price of $217.54.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $206.54 on Thursday. The stock has a market capitalization of $10.56 billion, a price-to-earnings ratio of 25.85, a PEG ratio of 5.57 and a beta of 1.38. The business’s 50 day moving average is $195.14 and its two-hundred day moving average is $207.90. Charles River Laboratories International, Inc. has a 12-month low of $174.92 and a 12-month high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. Charles River Laboratories International’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.72 earnings per share. Research analysts expect that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Charles River Laboratories International announced that its board has authorized a share repurchase program on Wednesday, August 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 9.6% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board of directors believes its stock is undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).